127 related articles for article (PubMed ID: 31677173)
1. Matrix metalloproteinases MMP-1, MMP-2, and MMP-13 are overexpressed in primary nodular melanoma.
Zamolo G; Grahovac M; Žauhar G; Vučinić D; Kovač L; Brajenić N; Grahovac B
J Cutan Pathol; 2020 Feb; 47(2):139-145. PubMed ID: 31677173
[TBL] [Abstract][Full Text] [Related]
2. Coordinate expression of membrane type-matrix metalloproteinases-2 and 3 (MT2-MMP and MT3-MMP) and matrix metalloproteinase-2 (MMP-2) in primary and metastatic melanoma cells.
Ohnishi Y; Tajima S; Ishibashi A
Eur J Dermatol; 2001; 11(5):420-3. PubMed ID: 11525948
[TBL] [Abstract][Full Text] [Related]
3. Immunolocalisation studies of matrix metalloproteinases-1, -2 and -3 in human melanoma.
Walker RA; Woolley DE
Virchows Arch; 1999 Dec; 435(6):574-9. PubMed ID: 10628799
[TBL] [Abstract][Full Text] [Related]
4. Expression of matrix metalloproteinase-2 and -9 and membrane-type 1 matrix metalloproteinase in melanocytic tumors of dogs and canine melanoma cell lines.
Docampo MJ; Cabrera J; Rabanal RM; Bassols A
Am J Vet Res; 2011 Aug; 72(8):1087-96. PubMed ID: 21801067
[TBL] [Abstract][Full Text] [Related]
5. Collagenase-3 (MMP-13) expression in cutaneous malignant melanoma.
Corte MD; Gonzalez LO; Corte MG; Quintela I; Pidal I; Bongera M; Vizoso F
Int J Biol Markers; 2005; 20(4):242-8. PubMed ID: 16398406
[TBL] [Abstract][Full Text] [Related]
6. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
[TBL] [Abstract][Full Text] [Related]
8. BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry.
Yaman B; Kandiloğlu G; Akalin T
Am J Dermatopathol; 2016 Feb; 38(2):113-20. PubMed ID: 26630683
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase expression in malignant melanomas: tumor-extracellular matrix interactions in invasion and metastasis.
Bodey B; Bodey B; Siegel SE; Kaiser HE
In Vivo; 2001; 15(1):57-64. PubMed ID: 11286131
[TBL] [Abstract][Full Text] [Related]
10. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma.
Väisänen AH; Kallioinen M; Turpeenniemi-Hujanen T
Hum Pathol; 2008 Mar; 39(3):377-85. PubMed ID: 18187184
[TBL] [Abstract][Full Text] [Related]
12. Matrilysin-1 (MMP-7) and MMP-19 are expressed by Paget's cells in extramammary Paget's disease.
Kuivanen T; Tanskanen M; Jahkola T; Impola U; Asko-Seljavaara S; Saarialho-Kere U
J Cutan Pathol; 2004 Aug; 31(7):483-91. PubMed ID: 15239678
[TBL] [Abstract][Full Text] [Related]
13. High collagenase-1 expression correlates with a favourable chemoimmunotherapy response in human metastatic melanoma.
Nikkola J; Vihinen P; Vlaykova T; Hahka-Kemppinen M; Kähäri VM; Pyrhönen S
Melanoma Res; 2001 Apr; 11(2):157-66. PubMed ID: 11333126
[TBL] [Abstract][Full Text] [Related]
14. Expression and prognostic role of MMP2, MMP9, MMP13, and MMP14 matrix metalloproteinases in sinonasal and oral malignant melanomas.
Kondratiev S; Gnepp DR; Yakirevich E; Sabo E; Annino DJ; Rebeiz E; Laver NV
Hum Pathol; 2008 Mar; 39(3):337-43. PubMed ID: 18045645
[TBL] [Abstract][Full Text] [Related]
15. Serum matrix metalloproteinase-2 in patients with malignant melanoma.
Wollina U; Hipler UC; Knöll B; Graefe T; Kaatz M; Kirsch K
J Cancer Res Clin Oncol; 2001 Oct; 127(10):631-5. PubMed ID: 11599800
[TBL] [Abstract][Full Text] [Related]
16. Loss of dipeptidyl peptidase IV immunostaining discriminates malignant melanomas from deep penetrating nevi.
Roesch A; Wittschier S; Becker B; Landthaler M; Vogt T
Mod Pathol; 2006 Oct; 19(10):1378-85. PubMed ID: 16829852
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression.
Hofmann UB; Westphal JR; Waas ET; Zendman AJ; Cornelissen IM; Ruiter DJ; van Muijen GN
Br J Cancer; 1999 Nov; 81(5):774-82. PubMed ID: 10555745
[TBL] [Abstract][Full Text] [Related]
18. Gallic acid inhibits the migration and invasion of A375.S2 human melanoma cells through the inhibition of matrix metalloproteinase-2 and Ras.
Lo C; Lai TY; Yang JS; Yang JH; Ma YS; Weng SW; Lin HY; Chen HY; Lin JG; Chung JG
Melanoma Res; 2011 Aug; 21(4):267-73. PubMed ID: 21734530
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value.
Väisänen A; Tuominen H; Kallioinen M; Turpeenniemi-Hujanen T
J Pathol; 1996 Nov; 180(3):283-9. PubMed ID: 8958806
[TBL] [Abstract][Full Text] [Related]
20. Expression of collagenase-1 (MMP-1) promotes melanoma growth through the generation of active transforming growth factor-beta.
Iida J; McCarthy JB
Melanoma Res; 2007 Aug; 17(4):205-13. PubMed ID: 17625450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
